MX2020003431A - Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona. - Google Patents

Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.

Info

Publication number
MX2020003431A
MX2020003431A MX2020003431A MX2020003431A MX2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A MX 2020003431 A MX2020003431 A MX 2020003431A
Authority
MX
Mexico
Prior art keywords
ioxolo
fluorobenzofuran
diona
pyrrol
indol
Prior art date
Application number
MX2020003431A
Other languages
English (en)
Spanish (es)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2020003431A publication Critical patent/MX2020003431A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2020003431A 2017-10-16 2018-10-16 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona. MX2020003431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572603P 2017-10-16 2017-10-16
PCT/US2018/056083 WO2019079299A1 (en) 2017-10-16 2018-10-16 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
MX2020003431A true MX2020003431A (es) 2020-07-29

Family

ID=64110166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003431A MX2020003431A (es) 2017-10-16 2018-10-16 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.

Country Status (16)

Country Link
US (3) US11407759B2 (https=)
EP (1) EP3697794B1 (https=)
JP (2) JP7776258B2 (https=)
KR (1) KR102891811B1 (https=)
CN (1) CN111315748B (https=)
AU (1) AU2018352384B2 (https=)
CA (1) CA3074037A1 (https=)
DK (1) DK3697794T3 (https=)
ES (1) ES3064009T3 (https=)
FI (1) FI3697794T3 (https=)
IL (1) IL273920B2 (https=)
MX (1) MX2020003431A (https=)
PL (1) PL3697794T3 (https=)
PT (1) PT3697794T (https=)
WO (1) WO2019079299A1 (https=)
ZA (1) ZA202002740B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EP3665176B1 (en) * 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu

Also Published As

Publication number Publication date
JP2020536944A (ja) 2020-12-17
EP3697794B1 (en) 2025-12-24
IL273920A (en) 2020-05-31
PT3697794T (pt) 2026-03-04
PL3697794T3 (pl) 2026-04-07
IL273920B2 (en) 2025-07-01
US12116374B2 (en) 2024-10-15
ZA202002740B (en) 2025-12-17
DK3697794T3 (da) 2026-02-02
JP2024001040A (ja) 2024-01-09
CN111315748B (zh) 2023-06-27
US20200239489A1 (en) 2020-07-30
US11407759B2 (en) 2022-08-09
ES3064009T3 (en) 2026-04-22
AU2018352384A1 (en) 2020-05-21
WO2019079299A1 (en) 2019-04-25
KR20200100615A (ko) 2020-08-26
EP3697794A1 (en) 2020-08-26
US20250115615A1 (en) 2025-04-10
CN111315748A (zh) 2020-06-19
IL273920B1 (en) 2025-03-01
CA3074037A1 (en) 2019-04-25
KR102891811B1 (ko) 2025-11-28
AU2018352384B2 (en) 2023-12-21
JP7776258B2 (ja) 2025-11-26
US20220348591A1 (en) 2022-11-03
BR112020007538A2 (pt) 2020-09-24
FI3697794T3 (fi) 2026-02-10

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CL2020000877S1 (es) Envase.
MX377710B (es) Anticuerpos monoclonales contra bcma.
CL2020000649S1 (es) Envase.
CL2020000652S1 (es) Envase.
CL2020000876S1 (es) Envase.
DK3402783T3 (da) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
CL2020000648S1 (es) Envase.
CL2020000650S1 (es) Envase.
MX2020003431A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol- 2,5-diona.
DK3665176T3 (da) Faste former af 3-(5-fluorbenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrol-2,5-dion
CL2020000663S1 (es) Envase.
CL2020000320S1 (es) Contenedor de alimentos.
CL2019001469S1 (es) Cepillo de dientes.
CL2020000184S1 (es) Contenedor.
CL2019001123S1 (es) Cepillo de dientes.
CL2019001121S1 (es) Cepillo de dientes.
CL2019001470S1 (es) Cepillo de dientes.
EA201792492A1 (ru) Aml-антигены и их применение
CL2019002581S1 (es) Envase de fragancia.
CL2019002582S1 (es) Envase de fragancia.
CL2020000244S1 (es) Porción de envase.
CL2020000240S1 (es) Porción de envase.
CL2020000241S1 (es) Porción de envase.